

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

- (1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING**
- (2) DISTRIBUTION OF CASH DIVIDEND**
- (3) APPOINTMENT OF DIRECTORS OF THE TENTH SESSION OF THE BOARD**
- (4) RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**
- (5) ELECTION OF CHAIRMAN AND DEPUTY CHAIRMAN OF THE BOARD AND APPOINTMENT OF SENIOR MANAGEMENT MEMBERS AND**
- (6) CHANGE IN COMPOSITION OF THE BOARD COMMITTEES**

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) announces that at its 2025 annual general meeting (the “**Shareholders’ Meeting**”) held on Thursday, April 16, 2026, all resolutions proposed were duly passed by way of poll. The Shareholders’ Meeting was convened by the board (the “**Board**”) of directors of the Company (the “**Directors**”).

Further details of the resolutions are set out in the notice of the Shareholders’ Meeting dated March 25, 2026 (the “**Notice**”) and the circular of the Company dated the same date (the “**Circular**”).

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

(1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING

As at the record date for the Shareholders’ Meeting, (i) the total number of Shares was 6,637,199,874 Shares, comprising 258,197,600 H Shares and 6,379,002,274 A Shares; and (ii) holders of 6,630,303,424 Shares (or by authorized proxies) were entitled to attend and vote on the resolutions proposed at the Shareholders’ Meeting. The total number of Shares for calculating the attendance of the Shareholders’ Meeting does not include the 6,896,450 A Shares repurchased and held in the stock repurchase account of the Company as treasury shares. The Company has not exercised the voting rights of the aforementioned Shares at the Shareholders’ Meeting. In addition, there were no Shares repurchased by the Company which are pending cancellation.

Each of Mr. Dai Hongbin, Mr. Zhang Lianshan, Mr. Sun Jieping, and Ms. Liu Xiaohan, is expected to (i) receive remuneration for the year ended December 31, 2025 pursuant to a service contract with the Company; (ii) become an insured person under the proposed liability insurance; and (iii) be subject to the proposed remuneration plan for Directors and Senior Management Members. Each of the aforementioned persons and the related Shareholder of the Company (in accordance with the Corporate Governance Standards for Listed Companies), namely Jiangsu Hengrui Pharmaceutical Group Co., Ltd. (江蘇恒瑞醫藥集團有限公司), a company in which Mr. Sun Piaoyang holds an 89.2% equity interest, was considered to have a material interest in (i) the remuneration of the Directors and Senior Management Members for 2025; (ii) the proposed purchase of liability insurance for Directors and Senior Management Members; and (iii) the proposed remuneration plan for Directors and Senior Management Members (i.e. resolutions no. 5, 6 and 9), from PRC law perspective, and were therefore required to and have abstained from voting on the relevant resolutions at the Shareholders' Meeting. Accordingly, the total number of Shares which were required to and have abstained from voting on the resolutions no. 5, 6 and 9 was 1,542,148,013 Shares.

Save as aforementioned, to the best knowledge, information and belief of the Directors, no other Shareholder was required under the Hong Kong Listing Rules to abstain from voting on the resolutions proposed at the Shareholders' Meeting. Further, no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the Shareholders' Meeting, and there were no Shares entitling the Shareholder to attend and abstain from voting in favor of the resolutions proposed at the Shareholders' Meeting as set out in Rule 13.40 of the Hong Kong Listing Rules.

Attendance at the Shareholders' Meeting

The Board is pleased to announce that the Shareholders' Meeting was held on Thursday, April 16, 2026 at 2:30 p.m. at No. 1288, Haik Road, Pudong New Area, Shanghai, PRC.

All Directors and secretary to the Board attended the Shareholders' Meeting either in person or by electronic means.

Set out below are the details of the Shareholders and authorized proxies present at the Shareholders' Meeting:

Number of Shareholders and authorised proxies		4,090
<i>Including:</i>	Number of A Shareholders	4,089
	Number of H Shareholders	1
Total number of Shares carrying voting rights (shares)		3,125,839,425
<i>Including:</i>	Total number of Shares carrying voting rights held by A Shareholders (shares)	2,990,489,566
	Total number of Shares carrying voting rights held by H Shareholders (shares)	135,349,859
Percentage of the total number of Shares carrying voting rights (%)		47.1447
<i>Including:</i>	Number of A Shares as a percentage of the total number of Shares carrying voting rights (%)	45.1034
	Number of H Shares as a percentage of the total number of Shares carrying voting rights (%)	2.0414

Poll Results of the Shareholders' Meeting

The poll results of the Shareholders' Meeting were as follows:

ORDINARY RESOLUTIONS		Number of votes cast (%)			Passed by Shareholders
		FOR	AGAINST	ABSTAIN	
1.	To consider and approve the work report of the Board of 2025.	3,113,755,897 (99.6134%)	788,098 (0.0252%)	11,295,430 (0.3614%)	Yes
2.	To consider and approve the Company's annual report of 2025.	3,113,741,817 (99.6130%)	800,578 (0.0256%)	11,297,030 (0.3614%)	Yes
3.	To consider and approve the Company's proposed profit distribution plan for 2025 and the proposed authorization to the Board to formulate the Company's interim dividend plan for 2026.	3,114,106,149 (99.6246%)	862,755 (0.0276%)	10,870,521 (0.3478%)	Yes
4.	To consider and approve the proposed re-appointment of auditors.	2,940,445,430 (94.0690%)	171,775,418 (5.4953%)	13,618,577 (0.4357%)	Yes
5.	To consider and approve the remuneration of the Directors and Senior Management Members of the Company for 2025.	1,568,257,008 (98.7782%)	8,168,774 (0.5145%)	11,229,456 (0.7073%)	Yes
6.	To consider and approve the proposed purchase of liability insurance for the Directors and Senior Management Members.	1,574,917,941 (99.1977%)	1,090,716 (0.0687%)	11,646,581 (0.7336%)	Yes
SPECIAL RESOLUTION		FOR	AGAINST	ABSTAIN	
7.	To consider and approve the resolution on the general mandate to issue Shares.	2,726,303,592 (87.2183%)	393,426,760 (12.5863%)	6,109,073 (0.1954%)	Yes
ORDINARY RESOLUTIONS		FOR	AGAINST	ABSTAIN	
8.	To consider and approve the proposed adoption of and amendments to certain corporate governance policies:				
	(a) the proposed amendments to the Rules of Procedure of the Shareholders' Meetings;	3,112,248,500 (99.5652%)	2,352,840 (0.0753%)	11,238,085 (0.3595%)	Yes
	(b) the proposed amendments to the Rules of Procedure of the Board; and	3,112,248,040 (99.5652%)	2,381,500 (0.0762%)	11,209,885 (0.3586%)	Yes
	(c) the adoption of the Management Policy for Remuneration of Directors and Senior Management Members.	3,112,180,120 (99.5630%)	2,443,673 (0.0782%)	11,215,632 (0.3588%)	Yes
9.	To consider and approve the proposed remuneration plan for the Directors and Senior Management Members.	1,575,154,669 (99.2126%)	1,256,037 (0.0791%)	11,244,532 (0.7082%)	Yes

10.	To consider and approve the proposed election of non-independent Directors of the tenth session of the Board:				
	(a) the election of Mr. Sun Piaoyang as an executive Director;	3,044,527,405 (97.3987%)	70,104,520 (2.2427%)	11,207,500 (0.3585%)	Yes
	(b) the election of Mr. Dai Hongbin as an executive Director;	3,047,292,569 (97.4872%)	67,136,724 (2.1478%)	11,410,132 (0.3650%)	Yes
	(c) the election of Ms. Feng Ji as an executive Director;	3,098,040,206 (99.1107%)	16,388,287 (0.5243%)	11,410,932 (0.3651%)	Yes
	(d) the election of Mr. Zhang Lianshan as an executive Director;	3,098,061,606 (99.1113%)	16,382,387 (0.5241%)	11,395,432 (0.3646%)	Yes
	(e) the election of Mr. Jiang Frank Ningjun as an executive Director; and	3,098,052,106 (99.1110%)	16,387,187 (0.5242%)	11,400,132 (0.3647%)	Yes
	(f) the election of Ms. Guo Congzhao as a non-executive Director.	3,089,057,445 (98.8233%)	25,376,748 (0.8118%)	11,405,232 (0.3649%)	Yes
11.	To consider and approve the proposed election of independent Directors of the tenth session of the Board by way of cumulative voting system:	Number of cumulative votes cast (%)			
	(a) the election of Mr. Lou Liguang as an independent non-executive Director;	2,930,169,331 (93.7402%)			Yes
	(b) the election of Mr. Zeng Qingsheng as an independent non-executive Director;	2,720,255,405 (87.0248%)			Yes
	(c) the election of Mr. Sun Jinyun as an independent non-executive Director; and	2,759,414,814 (88.2776%)			Yes
	(d) the election of Mr. Chow Kyan Mervyn as an independent non-executive Director.	2,928,059,885 (93.6728%)			Yes

Notes:

- (1) Please refer to the Notice and Circular for details of these resolutions.
- (2) All percentages are rounded to four decimal places. The percentage figures included in this table have been subject to rounding adjustments.
- (3) An ordinary resolution is passed by more than half of the votes casted in favor of it.
- (4) A special resolution is passed by more than two-thirds of the votes casted in favor of it.
- (5) The Company adopts the cumulative voting system for resolution 11 at the Shareholders' Meeting. When the independent Directors are elected through cumulative voting system at the Shareholders' Meeting, the maximum valid voting right of a voter is the product of (i) the number of Shares held by such Shareholder, and (ii) the number of the independent Directors to be elected (i.e. 4). A voter can cast all of his votes to one candidate or distribute his votes among several candidates. The independent Directors receiving votes representing more than half of the total number of Shares held by all Shareholders attending the Shareholders' Meeting (before cumulation) shall be elected.

Scrutiny of Vote-Counting and Lawyer's Certification

Pursuant to the Hong Kong Listing Rules, Tricor Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking in respect of H Shares at the Shareholders' Meeting.

Grandall Law Firm (Nanjing) witnessed the Shareholders' Meeting and certified that the convening and holding procedures, qualification of the attendees and convenor as well as voting procedures and voting results of the Shareholders' Meeting conformed to the requirements of the relevant PRC laws, rules and regulations, guidelines, and the Articles of Association of the Company. The voting results were lawful and valid.

(2) DISTRIBUTION OF CASH DIVIDEND

As the Profit Distribution Plan for 2025 was approved by the Shareholders at the Shareholders' Meeting, the Board is pleased to announce the distribution of a cash dividend of RMB2 (tax inclusive) per 10 Shares to all Shareholders.

The actual amount of cash dividend to be distributed will be adjusted according to the number of Shares held in the Company's stock repurchase account as of the record date for dividend distribution. In the event of any change in the Company's total share capital during the period from the date of this announcement to the record date for the implementation of the equity distribution, the Company intends to maintain the distribution ratio per Share unchanged and adjust the total distribution amount accordingly. In the event of any subsequent change in the total share capital, further announcement will be made regarding the specific adjustments.

It is expected that the cash dividend will be paid to the Shareholders within 2 months after the Shareholders' Meeting in accordance with the Articles of Association. The Company will separately announce the arrangements in relation to the distribution of dividend, including the record date, the period for closure of register of members, and the expected payment date for the distribution of dividend.

(3) APPOINTMENT OF DIRECTORS OF THE TENTH SESSION OF THE BOARD

At the Shareholders' Meeting, (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan and Mr. Jiang Frank Ningjun were re-elected as executive Directors; (ii) Ms. Guo Congzhao was re-elected as a non-executive Director; (iii) Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn were re-elected as independent non-executive Directors; and (iv) Mr. Lou Liguang was elected as an independent non-executive Director, of the tenth session of the Board. Mr. Sun Jieping was elected as an employee Director through the Company's employee Director election procedures at the Company's employee representative meeting held on March 2, 2026, whose term shall commence from the date of the Shareholders' Meeting. All the aforementioned Directors constitute the tenth session of the Board.

The tenth session of the Board became effective on the date of the Shareholders' Meeting and the term of office of each of the members of the tenth session of the Board shall be three years. For the details of the biographical information of each Director and other information required to be disclosed under Rule 13.51(2) of the Hong Kong Listing Rules, please refer to the announcement of the Company dated March 2, 2026 and the Circular. As of the date of this announcement, there has been no change to such information.

Upon the appointment of the aforementioned Directors becoming effective on the date of the Shareholders' Meeting, the Company entered into service contracts with each of the Directors. Each of the service contracts commences from the date of the Shareholders' Meeting to the date on which the term of office of the tenth session of the Board expires. The remuneration of the Directors will be determined by the Board upon recommendation from the Remuneration and Evaluation Committee with reference to their respective responsibilities, the Company's remuneration policy and the prevailing market conditions, and shall be in line with the remuneration plan for Directors as set out in the Circular and passed in the Shareholders' Meeting.

As at the date of this announcement, each of Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn had confirmed that (i) he meets the independence criteria as set out in Rule 3.13 of the Hong Kong Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Hong Kong Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

(4) RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Upon the election of the tenth session of the Board, Mr. Dong Jiahong ("**Mr. Dong**"), an independent non-executive Director of the ninth session of the Board, will retire from the positions of an independent non-executive Director, the chairperson of the Nomination Committee, a member of the Audit Committee and a member of the Strategy Committee, all effective from the date of the conclusion of the Shareholders' Meeting. Upon the retirement taking effect, Mr. Dong no longer holds any position in the Company. Mr. Dong has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited.

The Board would like to express its sincere gratitude to Mr. Dong for his valuable contributions and services to the Company during his tenure of office.

(5) ELECTION OF CHAIRMAN AND DEPUTY CHAIRMAN OF THE BOARD AND APPOINTMENT OF SENIOR MANAGEMENT MEMBERS

Following the conclusion of the Shareholders' Meeting, the tenth session of the Board held its first meeting (the "**Board Meeting**").

In the Board Meeting, the Board has resolved to elect (i) Mr. Sun Piaoyang as the chairman; and (ii) Mr. Dai Hongbin as the deputy chairman, of the tenth session of the Board, effective from the date of the Board Meeting until the expiration of the term of office of the tenth session of the Board.

In the Board Meeting, the Board has also appointed (i) Ms. Feng Ji as the president and the chief operating officer of the Company; (ii) Ms. Liu Xiaohan as the secretary to the Board; (iii) Mr. Zhang Lianshan and Mr. Jiang Frank Ningjun as the executive vice presidents of the Company; (iv) Mr. Sun Jieping and Mr. Zhu Guoxin as the senior vice presidents of the Company; and (v) Mr. Lau Kin Chun as the chief financial officer (financial controller) of the Company.

(6) CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

Upon the election and approval by the Directors in the Board Meeting, the composition of the Board committees under the tenth session of the Board is as follows:

Audit Committee

Mr. Zeng Qingsheng (*Chairperson*), Mr. Sun Jinyun, Mr. Lou Liguang, Mr. Chow Kyan Mervyn

Remuneration and Evaluation Committee

Mr. Sun Jinyun (*Chairperson*), Mr. Dai Hongbin, Mr. Zeng Qingsheng

Nomination Committee

Mr. Sun Jinyun (*Chairperson*), Ms. Feng Ji, Mr. Zeng Qingsheng

Strategy Committee

Mr. Sun Piaoyang (*Chairperson*), Mr. Dai Hongbin, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun, Ms. Guo Congzhao, Mr. Lou Liguang

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
April 16, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.